MAPRx Submits Letter to Senate Finance Committee on Drug Pricing Legislation

Today, the MAPRx Coalition and 28 of its members, national organizations representing patients, caregivers, and healthcare professionals, submitted a letter to the Senate Finance Committee on their recently released legislation, The 2019 Prescription Drug Pricing Reduction Act of 2019.

The Coalition greatly appreciates the Committee’s leadership in improving access to prescription drugs for the more than 44 million Americans who rely on Medicare Part D. MAPRx is especially appreciative of the Committee’s inclusion of an out-of-pocket cap in their legislation, which would lower costs for beneficiaries dealing with serious and chronic conditions. We are hopeful that the Committee will consider strengthening this provision by implementing a monthly cap and enabling the changes to go into effect earlier than the 2022 date presented in the original legislation.

The Committee should also carefully consider the changes made to the structure of the Part D benefit to ensure that they will not result in unintended consequences, such as increased costs for beneficiaries or reduced access to needed medications.

Click here to read MAPRx’s full letter to the Senate Finance Committee.